Up to date, Alzheimer’s Disease (AD) is considered as an “urgency” for public health, since it represents one of the most dramatic causes of death in adults. The drugs currently used for AD are only symptomatic, thus not curing the pathology, but only trying to slow or delay the progression of the pathology. Moreover, there is a total lack of early identification, with only “probable’’ or ‘‘possible’’ diagnosis of AD patients. With this review, we aimed to individuate and to highlight the most promising approaches for AD therapy and diagnosis. In this view, at the cutting-edge of innovation, nanocarriers as polymeric nanoparticles, liposomes, nanoassembly and dendrimers, have been studied and investigated in order to ameliorate the detection (in vitro and in vivo) and/or the therapeutic options in AD. In this review, the most outstanding nanomedicine-driven approaches in AD imaging/detection and treatments are summarized in order to help in individuating values and criticisms. Moreover, an overview of one of the most innovative strategies in AD management, namely theranostic nanomedicine, is reported and commented.

Nanotechnology and Alzheimer’s disease: What has been done and what to do’ / Ruozi, Barbara; Belletti, Daniela; Pederzoli, Francesca; Veratti, Patrizia; Forni, Flavio; Vandelli, Maria Angela; Tosi, Giovanni. - In: CURRENT MEDICINAL CHEMISTRY. - ISSN 0929-8673. - STAMPA. - 21:36(2014), pp. 4169-4185. [10.2174/0929867321666140716100056]

Nanotechnology and Alzheimer’s disease: What has been done and what to do’

RUOZI, Barbara;BELLETTI, Daniela;PEDERZOLI, FRANCESCA;VERATTI, PATRIZIA;FORNI, Flavio;VANDELLI, Maria Angela;TOSI, Giovanni
2014

Abstract

Up to date, Alzheimer’s Disease (AD) is considered as an “urgency” for public health, since it represents one of the most dramatic causes of death in adults. The drugs currently used for AD are only symptomatic, thus not curing the pathology, but only trying to slow or delay the progression of the pathology. Moreover, there is a total lack of early identification, with only “probable’’ or ‘‘possible’’ diagnosis of AD patients. With this review, we aimed to individuate and to highlight the most promising approaches for AD therapy and diagnosis. In this view, at the cutting-edge of innovation, nanocarriers as polymeric nanoparticles, liposomes, nanoassembly and dendrimers, have been studied and investigated in order to ameliorate the detection (in vitro and in vivo) and/or the therapeutic options in AD. In this review, the most outstanding nanomedicine-driven approaches in AD imaging/detection and treatments are summarized in order to help in individuating values and criticisms. Moreover, an overview of one of the most innovative strategies in AD management, namely theranostic nanomedicine, is reported and commented.
2014
21
36
4169
4185
Nanotechnology and Alzheimer’s disease: What has been done and what to do’ / Ruozi, Barbara; Belletti, Daniela; Pederzoli, Francesca; Veratti, Patrizia; Forni, Flavio; Vandelli, Maria Angela; Tosi, Giovanni. - In: CURRENT MEDICINAL CHEMISTRY. - ISSN 0929-8673. - STAMPA. - 21:36(2014), pp. 4169-4185. [10.2174/0929867321666140716100056]
Ruozi, Barbara; Belletti, Daniela; Pederzoli, Francesca; Veratti, Patrizia; Forni, Flavio; Vandelli, Maria Angela; Tosi, Giovanni
File in questo prodotto:
File Dimensione Formato  
Nanotechnology and Alzheimers Disease_ CMC Ruozi et al.pdf

Solo gestori archivio

Tipologia: Versione pubblicata dall'editore
Dimensione 7.67 MB
Formato Adobe PDF
7.67 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1017735
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 15
social impact